Dobesilic Acid

Dobesilic Acid

SCHEMBL214799

O=S(=O)(O)c1cc(O)ccc1O.[NaH]

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.70
HSD17B10 Q99714 3/20 0.70
HPGD P15428 1/20 0.70
HIF1A Q16665 1/20 0.70
PTGS1 P23219 1/20 0.61
EGFR P00533 1/20 0.56
GAA P10253 3/20 0.55
POLB P06746 2/20 0.55
GFER P55789 1/20 0.55
ALPL P05186 1/20 0.53
ALPI P09923 1/20 0.53
ALPG P10696 1/20 0.53
DNMT1 P26358 1/20 0.53
MCL1 Q07820 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ALDH1A1 P00352 3/20 0.49
PKM P14618 1/20 0.49
MPL P40238 2/20 0.43
NSD2 O96028 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dobesilic Acid SCHEMBL29389625 0.98 LMNA (0.72) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL232087 0.98 LMNA (0.72) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL344443 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL15364076 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL9790423 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL78224 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL370202 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL866670 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL10589964 0.95 HSD17B10 (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL78222 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116589673-A Flame-retardant hydrogenated bisphenol A polycarbonate and preparation method thereof 四川轻化工大学 2023-08-15 CN claimed
CN-115403740-A Biodegradable carbon dioxide-based polyurethane resin and preparation method thereof 聚源化学工业股份有限公司 2022-11-29 CN claimed
CN-111479913-B Compositions containing lanthanide metal complexes 罗地亚经营管理公司 2021-12-21 CN claimed
US-20210179975-A1 COMPOSITION CONTAINING LANTHANIDE METAL COMPLEX SPECIALTY OPERATIONS FRANCE (FR) 2021-06-17 US claimed
CN-112848582-A Bionic material and preparation method thereof 深圳第三代半导体研究院 2021-05-28 CN claimed
CN-112266456-A Biodegradable carbon dioxide-based polyurethane elastomer and preparation method thereof 中国科学院长春应用化学研究所 2021-01-26 CN claimed
CN-111479913-A Compositions containing lanthanide metal complexes 罗地亚经营管理公司 2020-07-31 CN claimed
US-20170231932-A1 METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS AmDerma Pharmaceuticals, LLC 2017-08-17 US claimed
US-9610256-B2 Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer AmDerma Pharmaceuticals, LLC (US) 2017-04-04 US claimed
US-9301931-B2 Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis AmDerma Pharmaceuticals, LLC (US) 2016-04-05 US claimed
US-20160058719-A1 Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis Lichten, Edward 2016-03-03 US claimed
US-20150065584-A1 Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis AmDerma Pharmaceuticals, LLC 2015-03-05 US claimed
US-8912171-B2 Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis AmDerma Pharmaceuticals, LLC (US) 2014-12-16 US claimed
US-20130296282-A1 Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis AmDerma Pharmaceuticals, LLC 2013-11-07 US claimed
WO-2004108414-A2 LITHOGRAPHIC PRINTING PLATE SYSTEM AND METHOD FOR MANUFACTURING THE PLATE SYSTEM DIGITAL MIND S.R.L. (IT) 2004-12-16 WO claimed
EP-0203468-B1 IMPROVED PHOTOGRAPHIC MATERIAL FOR TANNING DEVELOPMENT AND METHOD FOR OBTAINING A RELIEF IMAGE MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1989-03-08 EP claimed
US-4737441-A INCLUDING TWO DIFFERENT SUBSTITUTED 1,4-DIHYDRONBENZENES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1988-04-12 US claimed
EP-0203468-A2 Improved photographic material for tanning development and method for obtaining a relief image MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1986-12-03 EP claimed
US-11807023-B2 Pretreatment liquid, ink set, image recorded material, base material for image recording, method of producing base material for image recording, and image recording method FUJIFILM CORPORATION (JP) 2023-11-07 US disclosed
US-3954767-A HYPOCHOLESTEROLEMIC, HYPOTRIGLYCIDEMIC AND HYPOLIPIDEMIC ACTIVITY PROVESAN SA, 19, RUE DE LA CROIX D'OR, GENEVA, SWITZERLAND, A SWISS CORP. 1976-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160058719-A1 Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis IL2, IL2RA, IL5 LMNA 4181/4885HSD17B10 1497/4885HPGD 2149/4885
US-20150065584-A1 Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis IL2, IL2RA, IL5 LMNA 4181/4885HSD17B10 1497/4885HPGD 2149/4885
US-20170231932-A1 METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS IL2, IL2RA, IL5 LMNA 4181/4885HSD17B10 1497/4885HPGD 2149/4885
US-20130296282-A1 Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis IL2, IL2RA, IL5 LMNA 4181/4885HSD17B10 1497/4885HPGD 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.